Bristol-Myers Squibb just claimed ‘a breakthrough in cancer research’ — but there’s a catch (BMY)
|02/05/2018||Posted by BusinessMediaguide.Com under General World News||
- Bristol-Myers Squibb on Monday said that its cancer immunotherapy treatments succeeded in a late-stage trial in a particular group of non-small cell lung cancer patients.
- In patients that had a certain amount of tumor mutations, the treatment — a combination of Opdivo and Yervoy — was superior at keeping cancer patients’ disease from progressing than chemotherapy.
- BMS used a new way of evaluating cancer patients to get to this conclusion, which raised some eyebrows.
Bristol-Myers Squibb just had a make-or-break moment.
In a much-anticipated study, BMS showed how its drugs Opdivo and Yervoy stack up when treating lung cancer before other read more >>>